FDA Inspection 1102925 — HCG Manavata Cancer Centre
The FDA completed an inspection of HCG Manavata Cancer Centre on September 27, 2019 in Nashik. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). 1 citation was issued during this inspection. Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI) (VAI)
- End Date
- September 27, 2019
- Fiscal Year
- 2019
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Nashik (India)
Additional Details
Clinical BA/BE
Citations
| ID | CFR | Description |
|---|---|---|
| 7560 | 21 CFR 312.60 | FD-1572, protocol compliance |